145 related articles for article (PubMed ID: 37953768)
1. BIBR1532 inhibits proliferation and enhances apoptosis in multiple myeloma cells by reducing telomerase activity.
Zhang Y; Yang X; Zhou H; Yao G; Zhou L; Qian C
PeerJ; 2023; 11():e16404. PubMed ID: 37953768
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of telomerase using BIBR1532 enhances doxorubicin-induced apoptosis in pre-B acute lymphoblastic leukemia cells.
Bashash D; Zareii M; Safaroghli-Azar A; Omrani MD; Ghaffari SH
Hematology; 2017 Jul; 22(6):330-340. PubMed ID: 28054503
[TBL] [Abstract][Full Text] [Related]
3. BIBR1532, a Selective Telomerase Inhibitor, Enhances Radiosensitivity of Non-Small Cell Lung Cancer Through Increasing Telomere Dysfunction and ATM/CHK1 Inhibition.
Ding X; Cheng J; Pang Q; Wei X; Zhang X; Wang P; Yuan Z; Qian D
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):861-874. PubMed ID: 31419512
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
Que W; Chen J; Chuang M; Jiang D
APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
[TBL] [Abstract][Full Text] [Related]
5. miR-215-5p is an anticancer gene in multiple myeloma by targeting RUNX1 and deactivating the PI3K/AKT/mTOR pathway.
Liu S; Zhang Y; Huang C; Lin S
J Cell Biochem; 2020 Feb; 121(2):1475-1490. PubMed ID: 31498483
[TBL] [Abstract][Full Text] [Related]
6. A combination of the telomerase inhibitor, BIBR1532, and paclitaxel synergistically inhibit cell proliferation in breast cancer cell lines.
Shi Y; Sun L; Chen G; Zheng D; Li L; Wei W
Target Oncol; 2015 Dec; 10(4):565-73. PubMed ID: 25916999
[TBL] [Abstract][Full Text] [Related]
7. PLK4 inhibitor plus bortezomib exhibits a synergistic effect on treating multiple myeloma via inactivating PI3K/AKT signaling.
Xu B; Li J; Xu D; Ran Q
Ir J Med Sci; 2023 Apr; 192(2):561-567. PubMed ID: 35508865
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide and BIBR1532 synergistically inhibit breast cancer cell proliferation through attenuation of NF-κB signaling pathway.
Nasrollahzadeh A; Bashash D; Kabuli M; Zandi Z; Kashani B; Zaghal A; Mousavi SA; Ghaffari SH
Life Sci; 2020 Sep; 257():118060. PubMed ID: 32645343
[TBL] [Abstract][Full Text] [Related]
9. BIBR1532 Affects Endometrial Cell Proliferation, Migration, and Invasion in Endometriosis via Telomerase Inhibition and MAPK Signaling.
Zhao X; Luo D; Liu T; Zhang H; Xie Y; Kong W
Gynecol Obstet Invest; 2023; 88(4):226-239. PubMed ID: 37429261
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.
Zhang HR; Chen JM; Zeng ZY; Que WZ
J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505
[TBL] [Abstract][Full Text] [Related]
11. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.
Shi Y; Yan H; Frost P; Gera J; Lichtenstein A
Mol Cancer Ther; 2005 Oct; 4(10):1533-40. PubMed ID: 16227402
[TBL] [Abstract][Full Text] [Related]
12. [Regulatory Mechanism of Mangiferin Combined with Bortezomib on Malignant Biological Behavior of Burkitt Lymphoma and Its Effect on Expression of CXC Chemokine Receptors].
Yan ZM; Liu YQ; Xu QL; Lin J; Liu X; Zhu QP; Chen XJ; Liu TB; Lian XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1394-1402. PubMed ID: 37846690
[TBL] [Abstract][Full Text] [Related]
13. Diallyl thiosulfinate enhanced the anti-cancer activity of dexamethasone in the side population cells of multiple myeloma by promoting miR-127-3p and deactivating the PI3K/AKT signaling pathway.
He W; Fu Y; Zheng Y; Wang X; Liu B; Zeng J
BMC Cancer; 2021 Feb; 21(1):125. PubMed ID: 33549034
[TBL] [Abstract][Full Text] [Related]
14. Down regulation of human telomerase reverse transcriptase (hTERT) expression by BIBR1532 in human glioblastoma LN18 cells.
Lavanya C; Venkataswamy MM; Sibin MK; Srinivas Bharath MM; Chetan GK
Cytotechnology; 2018 Aug; 70(4):1143-1154. PubMed ID: 29546682
[TBL] [Abstract][Full Text] [Related]
15. Nanostructured lipid carrier co-delivering paclitaxel and doxorubicin restrains the proliferation and promotes apoptosis of glioma stem cells via regulating PI3K/Akt/mTOR signaling.
Chang L; Zhang Y; Li M; Zhao X; Wang D; Liu J; Zhou F; Zhang J
Nanotechnology; 2021 Mar; 32(22):. PubMed ID: 33690190
[TBL] [Abstract][Full Text] [Related]
16. Investigation of the effect of telomerase inhibitor BIBR1532 on breast cancer and breast cancer stem cells.
Doğan F; Özateş NP; Bağca BG; Abbaszadeh Z; Söğütlü F; Gasımlı R; Gündüz C; Biray Avcı Ç
J Cell Biochem; 2019 Feb; 120(2):1282-1293. PubMed ID: 30368861
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of DEPTOR induces apoptosis, increases chemosensitivity to doxorubicin and suppresses autophagy in RPMI-8226 human multiple myeloma cells in vitro.
Zhang H; Chen J; Zeng Z; Que W; Zhou L
Int J Mol Med; 2013 May; 31(5):1127-34. PubMed ID: 23503641
[TBL] [Abstract][Full Text] [Related]
18. The Small Molecule BIBR1532 Exerts Potential Anti-cancer Activities in Preclinical Models of Feline Oral Squamous Cell Carcinoma Through Inhibition of Telomerase Activity and Down-Regulation of TERT.
Altamura G; Degli Uberti B; Galiero G; De Luca G; Power K; Licenziato L; Maiolino P; Borzacchiello G
Front Vet Sci; 2020; 7():620776. PubMed ID: 33553285
[TBL] [Abstract][Full Text] [Related]
19. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
[TBL] [Abstract][Full Text] [Related]
20. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
Pene F; Claessens YE; Muller O; Viguié F; Mayeux P; Dreyfus F; Lacombe C; Bouscary D
Oncogene; 2002 Sep; 21(43):6587-97. PubMed ID: 12242656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]